Using Holmium-166 radioembolization to treat liver cancer
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
This study is testing if a new type of targeted radiation treatment called Holmium-166 can help people with advanced liver cancer feel better and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Brussels) |
| Trial ID | NCT06873269 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety and effectiveness of Holmium-166 (Ho-166) transarterial radioembolization (TARE) for patients with locally advanced hepatocellular carcinoma (HCC). It focuses on patients diagnosed with HCC who received Ho-166 TARE treatment between January 2010 and December 2024. The research involves a retrospective analysis of patient records, examining demographics, tumor characteristics, treatment side effects, and survival outcomes. The goal is to determine if this targeted radiation therapy can improve treatment outcomes for liver cancer patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 or older diagnosed with locally advanced HCC that is not amenable to surgical resection or ablation.
Not a fit: Patients with metastatic disease or those with severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new effective option for patients with advanced liver cancer.
How similar studies have performed: Other studies have shown promising results with similar radioembolization approaches, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 18 year or older * diagnosed with locally advanced HCC without extra-hepatic metastases * HCC must not be amendable to treatment by surgical resection or percutaneous radiofrequency ablation * after assessment by the investigator and multidisciplinary tumor board, the patient is considered suitable for protocol treatment with Holmium-166 TARE * ECOG performance status 0-2 * child-Pugh A-B * tumor response evaluable with mRECIST criteria during follow-up Exclusion Criteria: * prior treatment with any of the following treatment modalities for HCC: systemic therapy, hepatic radiation therapy * currently enrolled in clinical studies where patient receive investigational therapeutic drug * metastatic disease * concurrent malignancy * active contra-indications to angiography or selective catherization (i.e. severe vascular disease or bleeding diathesis) * uncontrolled and/or severe comorbidities (active infection, heart failure,...) with limited estimated life expectancy * history of or know allergic reactions to used compounds
Where this trial is running
Brussels
- UZ Brussel — Brussels, Belgium (Recruiting)
Study contacts
- Study coordinator: Helena Degroote
- Email: Helena.Degroote@uzbrussel.be
- Phone: 02476 3308
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.